Related Experiment Videos
Evaluation of a state-wide neonatal screening programme
Insights
South Australia
Area of Science:
- Medical Genetics
- Neonatal Screening
- Public Health Programs
Background:
- Established newborn screening for phenylketonuria in South Australia.
- Expanded screening to include galactosaemia, homocystinuria, hereditary tyrosinaemia, histidinaemia, maple syrup urine disease, and alpha 1-antitrypsin deficiency.
- Subsequently added hypothyroidism screening.
Purpose of the Study:
- Evaluate the utility of expanded newborn screening tests.
- Assess the effectiveness and impact of adding new screening panels.
- Determine which screening tests provide clinical benefit.
Main Methods:
- Retrospective analysis of screening program data.
- Inclusion of galactosaemia, homocystinuria, hereditary tyrosinaemia, histidinaemia, maple syrup urine disease, alpha 1-antitrypsin deficiency, and hypothyroidism.
- Monitoring of detection rates, repeat sample requests, and patient outcomes.
Main Results:
- Galactosaemia and hypothyroidism screening proved beneficial additions.
- Hereditary tyrosinaemia and alpha 1-antitrypsin deficiency screening led to repeat samples, anxiety, and no patient benefit.
- Homocystinuria, maple syrup urine disease, and histidinaemia were not effectively detected or yielded low detection rates.
Conclusions:
- Galactosaemia and hypothyroidism screening are valuable components of the South Australian newborn program.
- Screening for hereditary tyrosinaemia, alpha 1-antitrypsin deficiency, maple syrup urine disease, and histidinaemia was discontinued due to lack of benefit.
- Current newborn screening in South Australia includes phenylketonuria, hypothyroidism, galactosaemia, and homocystinuria.
Abstract:
A screening programme which was already established to detect phenylketonuria in the newborn period in South Australia was extended to include screening for galactosaemia, homocystinuria, hereditary tyrosinaemia, histidinaemia, maple syrup urine disease and severe alpha 1-antitrypsin deficiency for a trial period. Later, screening for hypothyroidism was introduced. Results suggest that screening for galactosaemia and hypothyroidism are useful additions to the programme. Screening for trrosinaemia and alpha 1-antitrypsin deficiency produced a high number of requests for repeat samples, causing anxiety and no positive benefit to patients. Homocystinuria, an eminently treatable condition, was not detected, nor was maple syrup urine disease, a much less readily treatable condition. Histidinaemia was detected only once. Screening for tyrosinaemia, alpha 1-antitrypsin deficiency, maple syrup urine disease and histidinaemia has been discontinued. Newborn screening in South Australia currently includes tests for phenylketonuria, hypothydroidism, galactosaemia and homocystinuria.